Literature DB >> 23299245

Altered cerebral protein synthesis in fragile X syndrome: studies in human subjects and knockout mice.

Mei Qin1, Kathleen C Schmidt, Alan J Zametkin, Shrinivas Bishu, Lisa M Horowitz, Thomas V Burlin, Zengyan Xia, Tianjiang Huang, Zenaide M Quezado, Carolyn Beebe Smith.   

Abstract

Dysregulated protein synthesis is thought to be a core phenotype of fragile X syndrome (FXS). In a mouse model (Fmr1 knockout (KO)) of FXS, rates of cerebral protein synthesis (rCPS) are increased in selective brain regions. We hypothesized that rCPS are also increased in FXS subjects. We measured rCPS with the L-[1-(11)C]leucine positron emission tomography (PET) method in whole brain and 10 regions in 15 FXS subjects who, because of their impairments, were studied under deep sedation with propofol. We compared results with those of 12 age-matched controls studied both awake and sedated. In controls, we found no differences in rCPS between awake and propofol sedation. Contrary to our hypothesis, FXS subjects under propofol sedation had reduced rCPS in whole brain, cerebellum, and cortex compared with sedated controls. To investigate whether propofol could have a disparate effect in FXS subjects masking usually elevated rCPS, we measured rCPS in C57Bl/6 wild-type (WT) and KO mice awake or under propofol sedation. Propofol decreased rCPS substantially in most regions examined in KO mice, but in WT mice caused few discrete changes. Propofol acts by decreasing neuronal activity either directly or by increasing inhibitory synaptic activity. Our results suggest that changes in synaptic signaling can correct increased rCPS in FXS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299245      PMCID: PMC3618394          DOI: 10.1038/jcbfm.2012.205

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  33 in total

1.  Evidence that fragile X mental retardation protein is a negative regulator of translation.

Authors:  B Laggerbauer; D Ostareck; E M Keidel; A Ostareck-Lederer; U Fischer
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

2.  Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function.

Authors:  J C Darnell; K B Jensen; P Jin; V Brown; S T Warren; R B Darnell
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

3.  The fragile X mental retardation protein inhibits translation via interacting with mRNA.

Authors:  Z Li; Y Zhang; L Ku; K D Wilkinson; S T Warren; Y Feng
Journal:  Nucleic Acids Res       Date:  2001-06-01       Impact factor: 16.971

4.  Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function.

Authors:  Y Q Zhang; A M Bailey; H J Matthies; R B Renden; M A Smith; S D Speese; G M Rubin; K Broadie
Journal:  Cell       Date:  2001-11-30       Impact factor: 41.582

5.  In vivo brain anatomy of adult males with Fragile X syndrome: an MRI study.

Authors:  Brian P Hallahan; Michael C Craig; Fiona Toal; Eileen M Daly; Caroline J Moore; Anita Ambikapathy; Dene Robertson; Kieran C Murphy; Declan G M Murphy
Journal:  Neuroimage       Date:  2010-08-12       Impact factor: 6.556

6.  Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.

Authors:  Emily K Osterweil; Dilja D Krueger; Kimberly Reinhold; Mark F Bear
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

7.  Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome.

Authors:  Zhong-Hua Liu; Tianjian Huang; Carolyn Beebe Smith
Journal:  Neurobiol Dis       Date:  2011-12-29       Impact factor: 5.996

8.  Effects of intravenous anesthetic agents on glutamate release: a role for GABAA receptor-mediated inhibition.

Authors:  D J Buggy; B Nicol; D J Rowbotham; D G Lambert
Journal:  Anesthesiology       Date:  2000-04       Impact factor: 7.892

9.  Propofol anesthesia does not alter regional rates of cerebral protein synthesis measured with L-[1-(11)C]leucine and PET in healthy male subjects.

Authors:  Shrinivas Bishu; Kathleen C Schmidt; Thomas V Burlin; Michael A Channing; Lisa Horowitz; Tianjiang Huang; Zhong-hua Liu; Mei Qin; B-K Vuong; Aaron J Unterman; Zengyan Xia; Alan Zametkin; Peter Herscovitch; Zenaide Quezado; Carolyn B Smith
Journal:  J Cereb Blood Flow Metab       Date:  2009-02-18       Impact factor: 6.200

10.  Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory.

Authors:  François V Bolduc; Kimberly Bell; Hilary Cox; Kendal S Broadie; Tim Tully
Journal:  Nat Neurosci       Date:  2008-09-07       Impact factor: 24.884

View more
  28 in total

Review 1.  Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders.

Authors:  Mustafa Sahin; Mriganka Sur
Journal:  Science       Date:  2015-10-15       Impact factor: 47.728

2.  Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.

Authors:  Mei Qin; Zachary Zeidler; Kristen Moulton; Leland Krych; Zengyan Xia; Carolyn B Smith
Journal:  Behav Brain Res       Date:  2015-05-12       Impact factor: 3.332

3.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

4.  Substitution of venous for arterial blood sampling in the determination of regional rates of cerebral protein synthesis with L-[1-11C]leucine PET: A validation study.

Authors:  Giampaolo Tomasi; Mattia Veronese; Alessandra Bertoldo; Carolyn B Smith; Kathleen C Schmidt
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-17       Impact factor: 6.200

5.  Measurement of regional rates of protein synthesis in human brain in vivo with L-[1-11C]-leucine PET.

Authors:  Carolyn B Smith; Kathleen C Schmidt
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 6.  Dysregulation and restoration of translational homeostasis in fragile X syndrome.

Authors:  Joel D Richter; Gary J Bassell; Eric Klann
Journal:  Nat Rev Neurosci       Date:  2015-09-09       Impact factor: 34.870

7.  The Fragile X proteins Fmrp and Fxr2p cooperate to regulate glucose metabolism in mice.

Authors:  Jeannette G Lumaban; David L Nelson
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

8.  Elevated CaMKIIα and Hyperphosphorylation of Homer Mediate Circuit Dysfunction in a Fragile X Syndrome Mouse Model.

Authors:  Weirui Guo; Laura Ceolin; Katie A Collins; Julie Perroy; Kimberly M Huber
Journal:  Cell Rep       Date:  2015-12-06       Impact factor: 9.423

9.  Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.

Authors:  Haruki Higashimori; Christina S Schin; Ming Sum R Chiang; Lydie Morel; Temitope A Shoneye; David L Nelson; Yongjie Yang
Journal:  J Neurosci       Date:  2016-07-06       Impact factor: 6.167

10.  Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.

Authors:  Daman Kumari; Aditi Bhattacharya; Jeffrey Nadel; Kristen Moulton; Nicole M Zeak; Anne Glicksman; Carl Dobkin; David J Brick; Philip H Schwartz; Carolyn B Smith; Eric Klann; Karen Usdin
Journal:  Hum Mutat       Date:  2014-12       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.